This multicenter phase I/II trial investigated the combination of bendamustine (BEN), lenalidomide (LEN) and dexamethasone (DEX) (BLD) in repeating 4week cycles as treatment for relapsed multiple myeloma (MM). Patients ≥ 18 years with symptomatic relapsed or refractory MM were enrolled. Phase I established maximum tolerated dose (MTD). Phase II assessed overall response rate (ORR) at the MTD. Secondary endpoints included progression free survival (PFS) and overall survival (OS). 29 evaluable patients were enrolled. Median age was 63 years (Range: 38-80). Median number of prior therapies was 3
Introduction
Recent advances in the therapy of multiple myeloma (MM), including high-dose chemotherapy, autologous stem cell transplant (SCT), and incorporation of thalidomide, lenalidomide (LEN) and bortezomib into treatment regimens, have improved outcomes. [1] [2] Nevertheless, 5-year overall survival (OS) remains less than 40%, 3 and there are few effective salvage regimens available for patients with disease resistant to novel agents. Therefore, there is a clear need for improved salvage regimens in MM.
LEN is an analogue of thalidomide that binds to cereblon 4 and subsequently effects transcription factors critical for MM growth, such as C/EBPβ 5 and IRF4. 6 In a pooled analysis of two large Phase III trials (MM-009 and MM-010) 7-8 with a median follow-up of 48 months, LEN plus dexamethasone (DEX) significantly improved overall response rate (ORR) (60.6 vs. 21.9%; p<0.001), complete response rate (CR) (15% vs. 2%; p<0.001) and median overall survival (OS) (38.0 vs. 31.6 months; p=0.045) compared to DEX alone. Median time to progression (TTP) during treatment with LEN-DEX was 13.4 months (vs. 4.6 mos. for DEX; p<0.001). 9 Bendamustine (BEN), a bifunctional agent, shares properties of alkylating agents and purine analogs. 10 In a Phase III study comparing BEN and prednisone versus melphalan and prednisone (MP) in previously untreated MM patients, comparable ORR were observed; however, a significantly higher number of patients treated with BEN and prednisone achieved CR (32 vs. 13%; p=0.007). 11 In a Phase I trial of BEN in patients with progressive disease after autologous For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From -SCT, the maximally tolerated dose (MTD) was 100 mg/m 2 on days 1 and 2 of repeating 28-day cycles. The ORR was 55%. 12 A lower dose of BEN (60 mg/m 2 ) was used together with thalidomide and prednisolone in a Phase I/II study involving patients with relapsed or refractory MM after autologous SCT or chemotherapy. The ORR in this study was 86%. 13 Given the different mechanisms of action ascribed to LEN and BEN, as well as results from previous studies successfully combining immunomodulatory drugs and alkylating agents such as MP plus thalidomide or MP plus LEN, [14] [15] [16] we sought to assess the feasibility and efficacy of a regimen combining BEN and LEN. In addition, we wanted to explore whether this combination has efficacy in patients with prior exposure to LEN. We report here a phase I/II clinical trial evaluating the safety, tolerability, and activity of BLD in patients with relapsed or refractory MM.
Methods

Study Design
This open-label, dose escalation study was performed at two centers in the USA (University of Pittsburgh Cancer Institute, Pittsburgh, PA and Karmanos Cancer Institute at Wayne State University, Detroit, MI). The Phase I portion was designed to determine the MTD (primary objective) of BEN and LEN in combination with a fixed dose of DEX for patients with relapsed or refractory MM.
In the Phase II portion of the study, an expansion cohort of patients was treated at the MTD to assess ORR. Secondary endpoints included evaluation of PFS, For personal use only. on April 19, 2017. by guest www.bloodjournal.org From -OS, and time to response (TTR). Individual patients stayed at the same dose level throughout study treatment unless they required dose reduction due to toxicity.
Patients and Eligibility
Eligible patients had relapsed or refractory MM, were ≥18 years old, had an Eastern Cooperative Oncology Group performance status of 0-2, and had an expected survival greater than six months. All patients had symptomatic MM and had previously been treated with at least one line of therapy, after which the patient had progressive or refractory disease. Prior LEN and/or autologous SCT were permissible. Patients had to have a total white blood cell count of at least 2 x 10 9 /L with an absolute neutrophil count of at least 1 x 10 9 /L, hemoglobin of at least 9 g/dL, platelet count of at least 75 x 10 9 /L, international normalized ratio 2-3 if on anticoagulation, total bilirubin ≤2.5mg/dL, aspartate aminotransferase and alanine aminotransferase ≤5 x institutional upper limit of normal, and creatinine After discontinuation of therapy, patients were followed every 3 months for the first 2 years, then every 6 months thereafter, or until death.
Statistical Analysis
The cut-off date for response and survival data was June 1, 2011. The patient demographics and baseline clinical characteristics were summarized as the number and percent of patients or as the median and range of values. Eligible patients who received at least one full cycle of BLD were evaluable for safety.
Patients who received at least 2 full cycles were evaluable for efficacy. Exact binomial 90% CIs were reported for toxicities and responses.
For personal use only. on April 19, 2017. by guest www.bloodjournal.org From -For patients who responded, the time to response (TTR) was calculated as the interval between the date on which the patient started protocol therapy and the date on which objective response (VGPR or PR) was first documented. PFS was calculated as the time interval between the date on which a patient first received regimen and the documented date of disease progression. OS was calculated as the time interval between the date on which a patient first received regimen and the documented date of death. Patients without an event were censored at the date they were last known to be in remission and alive for PFS, and alive for OS.
PFS and OS functions were estimated by the Kaplan-Meier method. To evaluate an association between β 2 microglobulin and response as well as between albumin, Glomerular Filtration Rate (GFR) and grade 3/4 neutropenia we used the Fisher's Exact Test.
Results
Patient Characteristics and Determination of MTD
Between June 2008 and February 2011, 29 patients were enrolled. We enrolled 15 patients into the phase I study and 14 patients into the phase II part of the study. All patients (n=29) had relapsed or refractory MM. Table 1 lists the baseline characteristics of these patients.
The median number of prior treatments was 3 (range 1-6). 97% of patients were previously treated with LEN, thalidomide or both. 66% (n=19) of patients had prior treatment with bortezomib.
Twenty patients (69%) had previously undergone autologous SCT.
The number of patients in each dosing cohort is detailed in neutropenia and one prolonged grade 3 thrombocytopenia, that was graded as a DLT. The MTD therefore was determined to be BEN 75 mg/m 2 and LEN 10 mg.
Drug Exposure and Safety
Treatment-related adverse events for all cycles that occurred with a frequency of 25% or greater are listed in Table 3 . The most common grade 3 or greater toxicities include neutropenia (62%; n=18 patients), thrombocytopenia (38%; n=11 patients), anemia (17%; n=5 patients), and leukopenia (38%; n=11 patients). In order to assess whether low albumin or decreased GFR contribute to increased toxicity of BLD we correlated grade 3/4 neutropenia with albumin < 
Efficacy
Twenty-five patients who received ≥ 2 cycles were evaluable for efficacy (Table   4 ). PR or better was observed in 52% (n=13) of patients. Six patients (24%) achieved a VGPR and 7 (28%) reached PR. Minimal response was observed in an additional 6 patients (24%), thus a total of 76% of patients had some degree of objective improvement. Among the patients achieving at least a PR, the median time to response was 1.6 months (95% CI; 1.6 to 3.5 months) ( Table 5) . 3 PR and 1 MR. We also correlated whether an increased β 2 microglobulin (≥3.5 mg/L) was associated with poorer outcome in patients treated with BLD. We For personal use only. on April 19, 2017. by guest www.bloodjournal.org From found no correlation between high β 2 microglobulin and poor response (SD and PD) (p=0.1753).
Efficacy in prognostic adverse groups
PFS and OS Data
Among the 25 evaluable patients, the median PFS was 6.1 months (95% CI; 3.7 to 9.4 months). The one-year PFS rate was 20% (95% CI; 6% to 41%) ( Figure   1A ). The median OS rate was not reached at the time of data evaluation (June 1, 2011 ( Table 5 ). The estimated 1-yr and 2-yr OS rates are 93% (95% CI; 59% to 99%) and 62% (95% CI; 25% to 84%), respectively ( Figure 1B) . After a median follow-up of 13.1 months (range 6-33), four patients (16%) died, all from progressive disease.
Discussion
Our findings indicate that the combination of BLD is a highly active regimen for patients with relapsed or refractory myeloma. The ORR including MR in our heavily pre-treated patient population was 76% with PR or better in 52%. The time to response including PR and VGPR was only 1.6 months (95% CI; 1.6 to 3.5 months) in our study. Sixty-nine % of the patients with disease refractory/relapsed to LEN and/or Thal responded to BLD suggesting this regimen overcomes resistance to IMiDs. Further, 60% of patients with abnormal cytogenetic/FISH analysis responded to BLD. In addition we found no correlation between high β 2 microglobulin and poor outcome suggesting that BLD might be effective in patients with adverse prognostic markers. Due to the small number of patients the results have to be interpreted with caution and further studies are For personal use only. on April 19, 2017. by guest www.bloodjournal.org From warranted to confirm our results. The 1-year OS was 93% and the median OS was not reached at a median follow-up of 13 months (95% CI; 6 to 33 months).
The frequent, rapid responses observed were very encouraging especially due to the fact that these patients were heavily pretreated, including prior immunomodulatory drug therapy in 97% of the patients.
In the clinical trials MM-009 and MM-010 patients were treated with LEN-DEX alone, with achievement of response rates (ORR of 60-61%) similar to the present trial. But in contrast to our study, patients enrolled in MM-009 and MM-010 were less heavily pretreated, were LEN-and bortezomib-naive and received higher doses of DEX [7] [8] . Other trials utilizing BEN in pretreated MM patients also produced high response rates. A dose escalation study of BEN alone, starting at 60 mg/m 2 and increasing up to 100 mg/m 2 showed an ORR of 55%, including MR, PR and CR. 12 Ponisch et al performed a phase I clinical trial testing the combination of BEN, prednisolone and thalidomide for relapsed or refractory MM after autologous SCT or conventional chemotherapy. 13 Using fixed doses of BEN (60 mg/m 2 ) and prednisolone (100 mg) with escalating doses of thalidomide (50, 100 and 200 mg), the response rate was 86% with 14% CRs, but a direct comparison to our data is difficult due to the use of different response criteria without FLCs for response assessment. 21 Further, patients in this trial were LENand bortezomib-naïve and were less heavily pretreated. Similar to our study, the major side effects were grade 3/4 neutropenia in 43% and grade 3/4 thrombocytopenia in 7% of patients. A dose escalation trial using bortezomib,
DEX and BEN in patients with relapsed or refractory MM and who failed
For personal use only. on April 19, 2017. by guest www.bloodjournal.org From bortezomib and DEX showed a PR rate of 57%, comparable to our trial. 22 Taken together, these studies demonstrate the activity of BEN in MM, administered either as a single agent or in combination with other medications.
As expected and in accordance with other trials, neutropenia (62% grade 3/4) and thrombocytopenia (38% grade 3/4) were the most commonly observed adverse events in our trial. Neutropenia was manageable with administration of G-CSF, dose adjustments or both.
Patients with pre-existing low-grade myelosuppression seemed to experience more hematologic toxicity. But the occurrence of neutropenia was not associated with decreased albumin or GFR suggesting that patients with hypoalbuminemia or impaired renal function do not have increased toxicity by BLD. This is in accordance with studies reporting that Bendamustine can be given in patients with renal impairment without dose reduction. [23] [24] Despite the relatively high frequency of grade 3 and 4 neutropenia, only one patient (3%) developed neutropenic fever with this treatment combination. Therefore the low rate of infection in our study does not support routine infection prophylaxis for relapsed MM patients treated with this regimen.
Other side effects such as diarrhea were generally mild and could be treated with supportive therapy such as loperamide. No thromboembolic events were documented. We did not observe unexpectedly high rates of skin rash, fatigue or peripheral neuropathies. As the high incidence of neuropathy in patients with MM may limit the use of neurotoxic agents, the low frequency of treatmentemergent neuropathy observed in this trial makes it a potentially attractive option in patients with relapsed disease.
For personal use only. on April 19, 2017. by guest www.bloodjournal.org From -In conclusion, the combination of BLD is an effective treatment option frequently inducing rapid responses in patients with relapsed or refractory MM who were heavily pre-treated. The high response rate in patients previously treated with LEN and/or thalidomide suggests that BEN has no cross-resistance with those drugs. One of the most frequent side effects was myelosuppression. Based on our experience, we recommend prophylaxis with G-CSF for patients with relapsed or refractory MM regardless of baseline myelosuppression. The lack of treatment-emergent neuropathy makes this combination especially attractive for patients with pre-existing neuropathy. 
